Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Cabozantinib in Japanese Patients With Advanced Hepatocellular Carcinoma After Prior Systemic Therapy
jRCT2080223960Phase 2Completed
- Sponsor
- Takeda
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cabozantinib in hepatocellular carcinoma (HCC) (2 cohorts), sponsored by Takeda. Started Jun 2018; status: completed.
02
Drugs
cabozantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080223960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223960.